New cholera vaccine is effective among people with HIV

doi:10.1136/bmj.330.7489.438-a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Scott Gottlieb

New York

A new, orally administered cholera vaccine has been shown to be effective against clinically significant cholera in an urban sub-Saharan population with a high prevalence of HIV infection.

The results offer one of the best possibilities for improved control of cholera, even among HIV infected people, who may not respond well to other cholera vaccines.

The results come from an evaluation in Beira, Mozambique—a city where the seroprevalence of HIV is 20% to 30%—of a mass immunisation programme with an oral cholera vaccine consisting of recombinant cholera toxin B subunit and killed whole cells (the rBS-WC vaccine) (New England Journal of Medicine 2005;352:757-67). The World Health Organization …